• BRIVIACT^® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures.
• Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose from day one.
• Pediatric epilepsy is the most common, serious neurological disorder among children and young adults, thought to affect nearly 470,000 children in the U.S.,^{1, 2}
• Indication comes less than 2 years after the launch of BRIVIACT in the U.S., building on existing adult monotherapy and adjunctive therapy indications, and broadening clinical application for UCB’s newest anti-epilepsy drug.

UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

UCB strengthens research capabilities with acquisition of Element Genomics, a Duke University biotech spin-off

CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.

UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018).